FebriDx® Improved Patient Streaming in the ED/Urgent Care
Improve patient streaming
Differentiate viral from bacterial infection1-2
Guide pathogen-specific testing1-2
High Negative Predictive Value1,3,4
― 99% NPV COVID-19*
― 99% NPV bacterial**
Rapid antimicrobial stewardship solution1-2
COVID-19 FebriDx
*based on a prevalence of 10-20% COVID-19
**patients febrile at the time of testing

Guide Pathogen-Specific Testing

COVID-19 FebriDx Process Flow
FebriDx® enables rapid and efficient patient streaming, improving flow through the hospital.5
FebriDx® triaging optimises use of limited isolation units improving infection prevention and control.
In real-world use at London North West NHS Trust, a FebriDx® led algorithm reduced the need for 2,859 patients to be admitted to isolation rooms with a 99.7% NPV (over a 3-month period).6
COVID-19 FebriDx Process Flow

The COVID-19 pandemic is placing a significant additional burden on all healthcare settings. Rapid identification of COVID-19 patients is critical to enable immediate isolation to prevent the spread of infection.

Molecular tests are available for SARS-CoV-2 but have been shown to have sub-optimal sensitivity and a turnaround time of ≥ 48 hours, causing delays in diagnosis which hampers patient isolation.4-5

SARS CoV-2 antigen tests are rapid and simple, but real-world performance has concluded low sensitivity.

During viral pandemics it is also imperative to ensure that patients with bacterial infections are not missed.6

Four studies prospectively evaluated the real-world diagnostic accuracy of FebriDx® for the detection of COVID-19 in hospitalised adults.3,4,6,10

FebriDx® was highly accurate in detecting COVID-19 infections, including cases missed by SARS-CoV-2 RT-PCR.3-4

FebriDx® viral negative patients can be rapidly cohorted to non-COVID-19 areas allowing viral positive patients to be immediately isolated whilst awaiting confirmatory PCR testing.3

In a study from Careggi University Hospital, ~45% of the patients who were negative for COVID-19 had a bacterial infection. FebriDx® was able to accurately differentiate bacterial infection from COVID-19.10

“FebriDx® could be rapidly deployed as a front door triage tool in hospitals and urgent care centers to overcome current issues of delayed diagnosis from PCR testing.”4

Utility of FebriDx in early identification of possible COVID-19 Infection

1. Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;50(5):420-29. https://doi.org/10.1080/07853890.2018.1474002
2. Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, et al. Diagnostic accuracy of FebriDx: A rapid test to detect immune responses to viral and bacterial upper respiratory infections. J Clin Med. 2017;6(10):94.
3. Karim N, Ashraf MZ, Naseem M, et al. Utility of FebriDx in early identification of possible COVID-19 infection. Res Square. 2020;Epub ahead of print. https://www.researchsquare.com/article/rs-25802/v1
4. Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. J Infect. 2020;Epub ahead of print. doi: 10.1016/j.jinf.2020.06.051
5. https://www.pathologyinpractice.com/story/34346/rapid-triaging-of-patients-during-covid-19-december-cover-article. Accessed April 28, 2021.
6. Houston H, Deas G, Naik S, et al. Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study. BMJ Open.. 2021;11:e049179. doi:10.1136/bmjopen-2021-049179
7. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiol. 2020:200432.
8. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;Eub ahead of print.
9. Cunha BA, Klein NC, Strollo S, Syed U, Mickail N, Laguerre M. Legionnaires’ disease mimicking swine influenza (H1N1) pneumonia during the ‘‘herald wave’’ of the pandemic. Heart Lung. 2010;39:242-48
10. Lagi F, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, et al. Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy. Int J Infect Dis. 2021;23:S1201-9712(21)00377-5. doi: 10.1016/j.ijid.2021.04.065